TABLE 2.
List of exomiRs associated with drug-response.
| Centralize the miRNAs ID | Pattern of expression | Cancer type | References |
|---|---|---|---|
| ExomiR-181b | Increased | Better response to 5-fluorouracil in Colorectal cancer | Nakajima et al. (2006) |
| ExomiR-140 and ExomiR-215 | Increased | Resistance to methotrexate, 5-fluorouacil, and Tomudex in human osteosarcoma and colon cancer cells | Song et al. (2009), Song et al. (2010) |
| ExomiR-19a | Increased | FOLFOX resistance in Advanced Colorectal Cancer Cases | Chen et al. (2013) |
| ExomiR-155 | Increased | Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma | Mikamori et al. (2017) |
| ExomiR‐34a | Decreased Increased |
Docetaxel resistance in castration-resistant prostate cancer Increased sensitivity to sorafenib in hepatocellular carcinoma cell lines |
Corcoran et al. (2014)
(Yang et al., 2014) |
| ExomiR-21 | Increased | Cisplatin resistance in gastric cancer (In mice) | Zheng et al. (2017) |
| ExomiR-122 | Decreased | Resistance to taxol in liver cancer | Sun et al. (2016) |
| ExomiR-128b | Loss of expression | Better response to gefitinib in non-small cell lung cancer | Weiss et al. (2008) |
| ExomiR-21 | Increased | Resistant to docetaxel-based chemotherapy in prostate cancer | Zhang et al. (2011a) |
| ExomiR-9 | Increased | Increase sensitivity of ovarian cancer to DNA damaging chemotherapy | Sun et al. (2013) |
| ExomiR‐125 b | Deletion | Better respond to chemotherapy with anthracycline in breast cancer | Climent et al. (2007) |
| ExomiR-195, ExomiR-455-3p, and ExomiR-10a miR-221 |
Increased Increased |
Temozolomide resistance in glioma |
Ujifuku et al. (2010)
Yang et al. (2017a) |
| ExomiR-29a and exomiR-100 | Increased | Drug resistance in pediatric acute promyelocytic leukemia | Zhang et al. (2011b) |
| ExomiR-142-3p and exomiR-17-92 | Increased | Glucocorticoid-resistant B cell precursor acute lymphoblastic leukemia | Sakurai et al. (2019) |
| ExomiR-99a, exomiR-100, and exomiR-125b | Increased | Resistance to daunorubicin and vincristine in pediatric acute lymphoblastic leukemia | Schotte et al. (2011) |
| ExomiR-142-5p, exomiR-199b, exomiR-217, exomiR-221, and exomiR-365a-3p | Decreased | Tyrosine kinase inhibitors resistance in chronic myelogenous leukemia | Yeh et al. (2016), Jiang et al. (2018), Klümper et al. (2020) |
| ExomiR-145-3p and exomiR-155 | Decreased | Bortezomib resistance in multiple myeloma | Amodio et al. (2019), Wu et al. (2020) |
| ExomiR-217 | Increased | Sensitizes AML to doxorubicin | Xiao et al. (2017) |
| ExomiR-143 | Increased | Enhances chemosensitivity of acute myeloid leukaemia to cytosine arabinoside | Zhang et al. (2020a) |
| ExomiR-181a/b | Increased | Fludarabine response in chronic lymphocytic leukemia | Zhu et al. (2012) |